Indeed, analyses of TCGA datasets of ovarian and bladder tumors indicated that MED12 expression levels can stratify the survival of patients with BRCA2-mutant tumors: low MED12 levels trended towards reduced survival of these patients, while high MED12 levels trended towards increased survival. This evidence concerns the gene MED12 and urinary bladder neoplasm.